0000000000374236

AUTHOR

Laura Bonmassar

showing 1 related works from this author

Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-sp…

2012

Cetuximab is a human/mouse chimeric IgG1 monoclonal antibody (mAb) to epidermal growth factor receptor, approved for colorectal carcinoma treatment in combination with chemotherapy. The immune-mediated effects elicited by its human fraction of crystallization moiety might critically contribute to the overall anti-tumor effectiveness of the antibody. We therefore investigated cetuximab ability to promote colon cancer cell opsonization and phagocytosis by human dendritic cells (DCs) that are subsequently engaged in antigen-cross presentation to cytotoxic T-lymphocyte (CTL) precursors. Human colon cancer cell lines were evaluated for susceptibility to DC-mediated phagocytosis before and after …

cetuximab; chemotherapy; danger signal; cytotoxic-T-lymphocytes; phagocytosisCancer ResearchColorectal cancerSettore MED/06 - Oncologia MedicaAntigen-Presenting CellsAntibodies Monoclonal Humanizedchemotherapydanger signalCross-PrimingAntigenAntigens NeoplasmCell Line TumorAntineoplastic Combined Chemotherapy ProtocolscetuximabHumansMedicineCytotoxic T cellCetuximabbusiness.industrySettore BIO/14Antibodies MonoclonalphagocytosisDendritic CellsDendritic cellmedicine.diseasecytotoxic-T-lymphocytedigestive system diseasesTumor antigenCTL*OncologyColonic NeoplasmsCancer cellImmunologyLeukocytes MononuclearCancer researchbusinessHT29 Cellscytotoxic-T-lymphocytesT-Lymphocytes Cytotoxicmedicine.drug
researchProduct